

World Summit on **O**BESITY AND **W**EIGHT **M**ANAGEMENT

June 27, 2022 | Webinar

De Novo Lipogenesis Inhibitors: As the other innovative agents for therapy of Metabolic Diseases (Obesity, NAFLD/NASH, CVD) - A narrative Review**Kulvinder Kochar Kaur***Scientific Director of Dr Kulvinder Kaur Centre for Human Reproduction*

For survival fatty acids is necessary, working as substrates for bioenergy generation, structural constituents along with signaling molecules. With their key part, evolutionary modes by cells for fatty acids formation from alternative carbon resources via an event labeled as de novo" lipogenesis (DNL). In spite of the knowledge of significance regarding it's up regulation abnormalities being correlated with numerous types of pathological conditions. Attempt at hampering core DNL enzymes inclusive of citrate/iso citrate carrier(CIC),ATP citrate lyase (ACLY), acetyl-coA carboxylase(ACC) along with fatty acid synthase(FAS) apparently should turn out to be a good therapeutic approach. Although numerous hurdles anticipated regarding effectiveness, selectiveness besides safety variable newer classes of synthetic DNL hampering agents have reached clinical stage generation besides becoming the basis for a newer class of treatment substances .Having earlier reviewed numerous articles regarding obesity along with its co-morbidities type2 Diabetes mellitus(T2DM) NAFLD /NASH here we have presented a narrative review regarding the evolutionary generation of DNL hampering agents as potential treatment agents .For this we review utilizing search engine PubMed, Google scholar; web of science; embase; Cochrane review library for which we have extracted data from earliest data with the recognition of significance of various enzymes besides their allosteric, covalent, transcriptional control of fatty acids generation& the problems encountered for their generation till date. Apart from obesity associated therapeutics their utility extends to acne vulgaris, various cancer therapies besides treating neuron generational diseases.

Biography

Kulvinder Kaur is the scientific director of DR Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab and India, where she manages the complicated cases of infertility. She graduated from LHMC Delhi in 1980 topping in medicine in all 3 medical colleges thereby getting the DR Devi Chand Gold medal from the late PM Smt Indira Gandhi & also topped in all the MBBS subjects prior to that eg anatomy, pathology, biochem etc. making her basics sound &later she managed the endocrine clinic in PGI Chandigarh during her MD days. Following that she reported the 40th world case hydrometrocolpos working in Saudi Arabia &has been working in the field of neuroendocrinology of obesity. GnRH control along with role of kisspeptins, prokineticins in human reproduction, AIDS & Cancer – during this period she managed to successfully treat the first case of nongestational choriocarcinoma of uterine body in a young girl medically thereby preserving her fertility-the first case in world literature of its kind .